feed,title,long_url,short_url
Benzinga,AstraZeneca/Merck's PARP Inhibitor In Late-Stage Breast Cancer Study To Enter Early Analysis,https://www.benzinga.com/general/biotech/21/02/19700495/astrazenecamercks-parp-inhibitor-in-late-stage-breast-cancer-study-to-enter-early-analysis,https://j.mp/37oj5W5
